Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

NCT05801783 is registered in ClinicalTrials.gov with Shanghai Yunying Medical Technology as lead sponsor.

NCT NCT05801783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05801783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Lead sponsor
Shanghai Yunying Medical Technology
Phase
Phase 1
Overall status
Unknown status
Start date
December 2, 2022
Completion date
December 2, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal carcinomatosis